Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer
Status:
Recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
This phase II multicentre randomized open-label study will assess the safety and efficacy of
Pembrolizumab in combination with standard chemotherapy in inflammatory breast cancer.
Pembrolizumab will be administered every 3 weeks during the neoadjuvant chemotherapy. Tissue
and blood samples will be collected pre- and post-treatment for translational research.